Molecular Adsorbent Recirculation System (MARS) is a form of extracorporeal detoxification system used as an artificial liver support system. Numerous studies have been published on the topic, with the majority of them describing the capability of MARS in removing albumin-bound toxins and improving systemic hemodynamics. Whether such improvement could be translated into survival benefit is still uncertain, given the paucity of randomized controlled trials available. The outcome of patients receiving MARS treatment is difficult to analyze because liver failure patients constitute a heterogeneous population and different subgroups carry different prognoses. An evidence-based recommendation on the timing of MARS initiation is not available and currently MARS is usually commenced for hyperbilirubinemia or presence of complications of liver failure. MARS is in general a safe procedure, but there are still potential complications that need to be cautioned, along with various operative issues that are worth attention. The future prospects of MARS would rely on the completion of adequately powered randomized controlled trials
StangeJ., MitznerS., RamlowW., GliescheT., HicksteinH., SchmidtR.A new procedure for the removal of protein bound drugs and toxins. ASAIO J1993; 39: M621–5.
2.
SteinerC., MitznerS.Experiences with MARS liver support therapy in liver failure: Analysis of 176 patients of the International MARS Registry. Liver2002; 22(suppl 2): S20–5.
3.
StangeJ., MitznerS.R., RislerT., ErleyC.M., LauchartW., GoehlH., KlammtS., PeszynskiP., FreytagJ., HicksteinH., LohrM., LiebeS., SchareckW., HoptU.T., SchmidtR.Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs1999; 23: 319–30.
LahdenperaA., KoivusaloA.M., VakkuriA., HockerstedtK., IsoniemiH.Value of albumin dialysis therapy in severe liver insufficiency. Transpl Int2005; 17: 717–23.
GuoL.M., LiuJ.Y., XuD.Z., LiB.S., HanH., WangL.H., ZhangW.Y., LuL.H., GuoX., SunF.X., ZhangH.Y., LiuX.D., ZhangJ.P., YaoY., HeZ.P., WangM.M.Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int2003; 23(suppl 3): S16–20.
8.
FaybikP., HetzH., BakerA., BittermannC., BerlakovichG., WerbaA., KrennC.G., SteltzerH.Extracorporeal albumin dialysis in patients with Amanita phalloides poisoning. Liver Int2003; 23(suppl 3): S28–33.
9.
HeemannU., TreichelU., LoockJ., PhilippT., GerkenG., MalagoM., KlammtS., LoehrM., LiebeS., MitznerS., SchmidtR., StangeJ.Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology2002; 36: 949–58.
10.
SenS., DaviesN.A., MookerjeeR.P., CheshireL.M., HodgesS.J., WilliamsR., JalanR.Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl2004; 10: 1109–19.
11.
TsaiM.H., ChenY.C., WuC.S., HoY.P., FangJ.T., LienJ.M., YangC., ChuY.Y., LiuN.J., LinC.H., ChiuC.T., ChenP.C.Extracorporal liver support with molecular adsorbents recirculating system in patients with hepatitis B-associated fulminant hepatic failure. Int J Clin Pract2005; 59: 1289–94.
12.
DeschenesM., BelleS.H., KromR.A., ZettermanR.K., LakeJ.R.Early allograft dysfunction after liver transplantation: A definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation1998; 66: 302–10.
13.
Di CampliC., ZoccoM.A., GaspariR., NoviM., CandelliM., SantoliquidoA., FloreR., TondiP., ProiettiR., GasbarriniG., PolaP., GasbarriniA.The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transplant Proc2005; 37: 2551–3.
14.
FaubionW.A., GuicciardiM.E., MiyoshiH., BronkS.F., RobertsP.J., SvingenP.A., KaufmannS.H., GoresG.J.Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest1999; 103: 137–45.
15.
HughesR.D., CochraneA.M., ThomsonA.D., Murray-LyonI.M., WilliamsR.The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol1976; 57: 348–53.
16.
van de KerkhoveM.P., de JongK.P., RijkenA.M., de PontA.C., van GulikT.M.MARS treatment in posthepatectomy liver failure. Liver Int2003; 23(suppl 3): S44–51.
17.
DeMatteoR.P., FongY., BlumgartL.H.Surgical treatment of malignant liver tumours. Baillieres Best Pract Res Clin Gastroenterol1999; 13: 557–74.
LynchP., HassaneinT., HilsenbeckR., StangeJ., BleiA.T.Grading of hepatic encephalopathy in a controlled trial of MARS. Performances of two scales. Hepatology2004; 40: 508A.
20.
ArroyoV., GinesP., GerbesA.L., DudleyF.J., GentiliniP., LaffiG., ReynoldsT.B., Ring-LarsenH., ScholmerichJ.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology1996; 23: 164–76.
21.
MitznerS.R., StangeJ., KlammtS., RislerT., ErleyC.M., BaderB.D., BergerE.D., LauchartW., PeszynskiP., FreytagJ., HicksteinH., LoockJ., LohrJ.M., LiebeS., EmmrichJ., KortenG., SchmidtR.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl2000; 6: 277–86.
22.
United Network for Organ Sharing.Policy 3.6.4: Organ Distribution: Allocation of Livers.Degree of Medical Urgency. June 25, 1999.
23.
MitznerS.R., KlammtS., PeszynskiP., HicksteinH., KortenG., StangeJ., SchmidtR.Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher2001; 5: 417–22.
24.
EvenepoelP., MaesB., WilmerA., NevensF., FeveryJ., KuypersD., BammensB., VanrenterghemY.Detoxifying capacity and kinetics of the molecular adsorbent recycling system. Contribution of the different inbuilt filters. Blood Purif2003; 21: 244–52.
25.
WeissJ.S., GautamA., LauffJ.J., SundbergM.W., JatlowP., BoyerJ.L., SeligsonD.The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med1983; 309: 147–50.
26.
ReedR.G., DavidsonL.K., BurringtonC.M., PetersT.Jr.. Non-resolving jaundice: Bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin. Clin Chem1988; 34: 1992–4.
27.
MatsubaraS., OkabeK., OuchiK., OwadaY.Blood purification of bilirubin and bile acids by plasma exchange for patients with liver failure. Tohoku J Exp Med1986; 150: 83–90.
28.
KoivusaloA.M., VakkuriA., HockerstedtK., IsoniemiH.Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc2005; 37: 3315–7.
29.
InderbitzinD., MuggliB., RinggerA., BeldiG., GassM., GloorB., UehlingerD., RegliB., ReichenJ., CandinasD.Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J Gastrointest Surg2005; 9: 1155–62.
30.
KhooA.L., ThamL.S., LimG.K., LeeK.H.Hypoglycemia in nondiabetic patients undergoing albumin dialysis by molecular adsorbent recirculating system. Liver Transpl2003; 9: 949–53.
31.
BregmanH., DaugirdasJ.T., IngT.S.Complications in hemodialysis. In: DaugirdasJ.T., IngT.S., eds. Handbook of dialysis.Boston: Little Brown, and Company; 1994. p 149–69.
32.
SenS., YtreboL.M., RoseC., FuskevaagO.M., DaviesN.A., NedredalG.I., WilliamsR., RevhaugA., JalanR.Albumin dialysis: A new therapeutic strategy for intoxication from protein-bound drugs. Intensive Care Med2004; 30: 496–501.
33.
KhurooM.S., KhurooM.S., FarahatK.L.Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: A meta-analysis. Liver Transpl2004; 10: 1099–106.
34.
ChoiJ.Y., BaeS.H., YoonS.K., ChoS.H., YangJ.M., HanJ.Y., AhnB.M., ChungK.W., SunH.S., KimD.G.Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation – a pilot study. Liver Int2005; 25: 740–5.
35.
RoncoC., InguaggiatoP., D'IntiniV., ColeL., BellomoR., PoulinS., BordoniV., CrepaldiC., GastaldonF., BrendolanA., TrairakP., KhajohnT.The role of extracorporeal therapies in sepsis. J Nephrol2003; 16(suppl 7): S34–41.
36.
LuoH.T., GuoL.M., WuM., LiuQ.M., WangM.M.Therapeutic application of molecular adsorbents recirculating system in various pathogenic MODS/MOF patients. Chin Med J (Engl)2005; 118: 1113–7.
37.
LuoH.T., WuM., WangM.M.Case report of the first Severe Acute Respiratory Syndrome patient in China: Successful application of extracorporeal liver support MARS therapy in multiorgan failure possibly induced by severe acute respiratory syndrome. Artif Organs2003; 27: 847–9.
38.
StangeJ., MitznerS.R., KlammtS., FreytagJ., PeszynskiP., LoockJ., HicksteinH., KortenG., SchmidtR., HentschelJ., SchulzM., LohrM., LiebeS., SchareckW., HoptU.T.Liver support by extracorporeal blood purification: A clinical observation. Liver Transpl2000; 6: 603–13.
39.
LameschP., JostU., SchreiterD., ScheibnerL., BeierO., FangmannJ., HaussJ.Molecular adsorbant recirculating system in patients with liver failure. Transplant Proc2001; 33: 3480–2.
40.
SorkineP., Ben AbrahamR., SzoldO., BidermanP., KidronA., MerchavH., BrillS., OrenR.Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med2001; 29: 1332–6.
41.
AwadS.S., SwanikerF., MageeJ., PunchJ., BartlettR.H.Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery2001; 130: 354–62.
42.
SchmidtL.E., SorensenV.R., SvendsenL.B., HansenB.A., LarsenF.S.Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl2001; 7: 1034–9.
43.
KellersmannR., GasselH.J., BuhlerC., ThiedeA., TimmermannW.Application of Molecular Adsorbent Recirculating System in patients with severe liver failure after hepatic resection or transplantation: Initial single-centre experiences. Liver2002; 22(suppl 2): S56–8.
44.
ChenS., ZhangL., ShiY., YangX., WangM.Molecular adsorbent recirculating system: Clinical experience in patients with liver failure based on hepatitis B in China. Liver2002; 22(suppl 2): S48–51.
45.
WilmerA., NevensF., EvenepoelP., HermansG., FeveryJ.The Molecular Adsorbent Recirculating System in patients with severe liver failure: Clinical results at the K.U. Leuven. Liver2002; 22(suppl 2): S52–5.
46.
JalanR., SenS., SteinerC., KapoorD., AlisaA., WilliamsR.Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol2003; 38: 24–31.
47.
CovicA., GoldsmithD.J., Gusbeth-TatomirP., VolovatC., DimitriuA.G., CristogelF., BizoA.Successful use of molecular absorbent regenerating system (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver Int2003; 23(suppl 3): S21–7.
48.
Di CampliC., SantoroM.C., GaspariR., MerraG., Zileri Dal VermeL., ZoccoM.A., PiscagliaA.C., Di GioacchinoG., NoviM., SantoliquidoA., FloreR., TondiP., ProiettiR., GasbarriniG., PolaP., GasbarriniA.Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure. Transplant Proc2005; 37: 2547–50.
49.
LaiW.K., HaydonG., MutimerD., MurphyN.The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure. Intensive Care Med2005; 31: 1544–9.
